Category: Press Releases

Drug Delivery, Featured, Press Releases

BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide

Dec 2, 2024

VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery...

Continue Reading

Drug Delivery, Press Releases

BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

Nov 25, 2024

VANCOUVER, BC / ACCESSWIRE / November 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its...

Continue Reading

Drug Delivery, Featured, Press Releases

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

Oct 29, 2024

VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that it has initiated...

Continue Reading

Press Releases

Terry Lynch Joins BioNxt as Capital Markets Advisor

Oct 7, 2024

VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch has...

Continue Reading

Drug Delivery, Press Releases

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

Mar 18, 2024

Based on the recent success of its toxicity and comparative pharmacokinetic (“PK”) studies the Company is advancing towards human comparative bioavailability studies on an expedited...

Continue Reading

Drug Delivery, Featured, Press Releases

BIONXT REPORTS SUCCESSFUL RESULTS FROM ODF CLADRIBINE PK STUDY

Mar 13, 2024

The animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between the Company’s ODF product and the name-brand reference...

Continue Reading

Drug Delivery, Press Releases

BIONXT REPORTS COMPLETION OF ODF CLADRIBINE PK STUDY

Mar 4, 2024

BioNxt is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis...

Continue Reading

Press Releases

BioNxt Reports Successful Results From ODF Cladribine Toxicity Study

Feb 8, 2024

VANCOUVER, BC – February 7, 2024 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

BIONXT RECEIVES DELIVERY OF PREMIUM COMMERCIAL COATING AND CUTTING EQUIPMENT FOR COMMERCIAL MANUFACTURING OF DRUG DELIVERY PRODUCTS

Dec 12, 2023

VANCOUVER, BC – December 12, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

BIONXT ACCELERATES CLADRIBINE ODF CLINICAL AND COMMERCIALIZATION STRATEGY FOR MULTIPLE SCLEROSIS TREAMENT

Nov 20, 2023

VANCOUVER, BC – November 20, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT REPORTS ON NEW CLADRABINE ODF PRODUCT DEVELOPMENT AND COMMERCIALIZATION PROGRAM

Nov 15, 2023

VANCOUVER, BC – November 15, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT SIGNS DEFINITIVE AGREEMENT FOR 100% ACQUISITION OF IP AND CO-DEVELOPMENT OF CLADRIBINE ODF DRUG REFORMULATION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Nov 13, 2023

VANCOUVER, BC – November 13, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading